GLP-1 and Health Insurance: Which Plans Cover What in 2026

Introduction

Insurance coverage for GLP-1 drugs in 2026 splits along three lines: type 2 diabetes (almost universal), cardiovascular and obstructive sleep apnea indications (broad and growing), and weight loss alone (still spotty). Whether a patient pays $30 or $1,300 a month for the same drug depends entirely on which plan they have and which clinical indication their physician documents.

This article walks through the actual coverage stance of major commercial insurers, Medicare, Medicaid, and the major employer health plans for 2026. Where possible we cite formulary documents, public statements, and disclosed actuarial data. Coverage details change quickly, and patients should verify current status with their specific plan.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What’s the Basic Insurance Landscape for GLP-1 Drugs?

Three indication categories drive coverage decisions in 2026:

Quick Answer: UnitedHealthcare, Cigna, Anthem, and Aetna all cover Wegovy® for cardiovascular indications with prior authorization

Type 2 diabetes. Universally covered across commercial insurance, Medicare, Medicaid, VA, and TRICARE. Ozempic®, Mounjaro®, Trulicity®, Rybelsus®, and Bydureon all have established coverage when prescribed for diabetes. Prior authorization is common but rarely denied for documented diabetes diagnoses.

Cardiovascular risk reduction in obesity. Covered broadly across commercial insurance and Medicare Part D since the FDA added the cardiovascular indication to Wegovy in March 2024 based on SELECT trial data (Lincoff et al. 2023 NEJM). Prior authorization typically requires documented cardiovascular disease.

Obesity alone. Coverage varies enormously. About 50% of large employer plans cover Wegovy or Zepbound® for obesity in 2025, up from roughly 25% in 2023. Most state Medicaid programs do not cover obesity-indicated GLP-1s. Medicare Part D cannot cover them due to statutory exclusion.

Newer indications including obstructive sleep apnea (Zepbound, approved December 2024) and pending kidney disease and MASH approvals are creating additional coverage pathways for patients who don’t qualify under obesity alone.

How Does UnitedHealthcare Handle GLP-1 Coverage?

UnitedHealthcare’s commercial formulary in 2026 covers Ozempic and Mounjaro for type 2 diabetes on preferred brand tiers. Wegovy and Zepbound are covered for FDA-approved indications including cardiovascular risk reduction (Wegovy) and obstructive sleep apnea (Zepbound).

UnitedHealthcare’s Optum Rx pharmacy benefit manager applies prior authorization that typically requires documentation of qualifying diagnosis, BMI threshold for weight-related indications, and trial of lifestyle intervention. The standard BMI threshold is 30, or 27 with at least one obesity-related comorbidity.

The company’s largest commercial plans cover anti-obesity GLP-1s for employer groups that opt in, with about 55% of large employer groups choosing the obesity coverage rider in 2026 surveys. Smaller and middle-market employer plans show lower opt-in rates, around 30 to 40%.

UnitedHealthcare’s Medicare Advantage Part D plans cover Wegovy for cardiovascular indications and Zepbound for OSA, consistent with the CMS guidance issued in 2024.

What About Cigna?

Cigna’s Express Scripts pharmacy benefit manager covers Ozempic, Mounjaro, Wegovy, and Zepbound for FDA-approved indications across most commercial formularies. The company moved aggressively in 2024 to include cardiovascular-indicated Wegovy after SELECT data was published.

For obesity-only coverage, Cigna’s standard commercial formulary includes Wegovy and Zepbound at tier 3 with prior authorization. The PA criteria typically require BMI of 30 or BMI of 27 with comorbidities, three months of documented lifestyle modification, and ongoing weight loss benchmarks for continued coverage.

Cigna runs a separate program called EncircleRx for employer clients that includes GLP-1 utilization management with negotiated pricing and outcomes guarantees. The program covers an estimated 1 million employer-sponsored lives in 2026.

How Does Anthem and Elevance Health Handle Coverage?

Elevance Health, Anthem’s parent company, covers GLP-1s broadly for FDA-approved indications through its CarelonRx pharmacy benefit manager. Type 2 diabetes coverage is universal. Cardiovascular-indicated Wegovy gained coverage in mid-2024.

Anthem’s commercial formularies in 2026 cover Wegovy and Zepbound for obesity at tier 3 or 4 with prior authorization for employer plans that opt in. Roughly half of Anthem’s large employer commercial book has obesity coverage included as of 2026.

Elevance has been a vocal advocate for value-based contracting on GLP-1s, with several outcomes-based agreements with Eli Lilly and Novo Nordisk that tie rebates to weight loss achievement and persistence. The terms of these contracts are not public but have reportedly improved pricing on Wegovy and Zepbound by 5 to 15% versus standard rebates.

What About Aetna and CVS Health?

CVS Health, Aetna’s parent company, covers GLP-1s through Aetna commercial plans and CVS Caremark pharmacy benefit management. Coverage for diabetes indications is universal. Wegovy gained broad coverage for cardiovascular indications in 2024.

Aetna’s standard commercial formulary covers Wegovy and Zepbound for obesity for employer plans that opt in. The PA requirements are similar to other major insurers: BMI threshold, comorbidity documentation, lifestyle intervention trial, and ongoing weight loss benchmarks.

CVS Caremark runs a program called Caremark Cost Saver that includes step therapy and utilization management for GLP-1s. Some employer clients use the program to manage costs, while others bypass it for broader coverage. The variation contributes to the wide range of patient experiences with Aetna coverage.

Does Kaiser Permanente Cover GLP-1s?

Kaiser Permanente is a closed-system integrated delivery network that operates differently from traditional insurance. The Kaiser system covers GLP-1s for diabetes through its internal formulary in all regions. Weight loss coverage varies by region and plan.

Kaiser’s California regions cover Wegovy and Zepbound for obesity in many commercial plans with prior authorization. The company’s Northwest, Hawaii, and Mid-Atlantic regions have similar coverage. Kaiser’s smaller regions in Colorado and Washington may have tighter restrictions.

Kaiser publishes annual formulary documents that detail current coverage. Patients should check the Kaiser pharmacy benefit document specific to their region and plan year for current status.

How Do Blue Cross Blue Shield Plans Handle GLP-1?

The Blue Cross Blue Shield Association is a federation of 33 independent state Blue plans, and coverage varies substantially across the system. Some patterns hold:

Diabetes indications are covered everywhere. Cardiovascular-indicated Wegovy is covered in essentially all Blue plans as of 2026, since CMS guidance and commercial market alignment have driven this change.

Obesity-only coverage varies by state Blue plan and by employer rider. Anthem (which operates Blue Cross Blue Shield plans in 14 states) takes one approach, Health Care Service Corporation (which operates Blues in five states) takes another, and independent Blues like Florida Blue, Highmark, and Independence Blue Cross each set their own policies.

The Federal Employee Program (FEP) administered by the Blue Cross Blue Shield Association covers anti-obesity GLP-1s in all 2026 plans as part of the broader FEHBP coverage requirement.

What Does Medicare Cover?

Medicare Part D coverage for GLP-1s in 2026 follows the indication pathway. Diabetes indications (Ozempic, Mounjaro, Rybelsus, Trulicity) are universally covered. Cardiovascular-indicated Wegovy is covered following the March 2024 FDA approval and CMS guidance. OSA-indicated Zepbound is covered following the December 2024 FDA approval.

Pure weight loss coverage is statutorily prohibited under Medicare Part D by 42 U.S.C. § 1395w-102(e)(2). This exclusion has been in place since the Part D benefit launched in 2006 and would require an act of Congress to change. The Treat and Reduce Obesity Act has been introduced in every Congress since 2012 without passage.

Medicare Part D out-of-pocket spending is capped at $2,000 annually starting in 2025 under the Inflation Reduction Act. For Wegovy or Zepbound at retail prices over $12,000 per year, most covered beneficiaries reach the cap quickly.

Key Takeaway: About 16 state Medicaid programs cover anti-obesity GLP-1s as of early 2026

What Does Medicaid Cover?

Medicaid coverage of GLP-1s varies by state. As of early 2026, about 16 state Medicaid programs cover Wegovy or Zepbound for obesity, including California, New York, Pennsylvania, Massachusetts, Connecticut, Maryland, Minnesota, Oregon, Washington, Virginia, North Carolina, New Jersey, Rhode Island, Illinois, Vermont, and Delaware.

The remaining states either limit coverage to specific high-comorbidity populations or do not cover anti-obesity GLP-1s at all. Some states cover them only for Medicaid managed care members in specific plans, not in fee-for-service Medicaid.

All state Medicaid programs cover semaglutide and tirzepatide for diabetes indications under federal Medicaid drug rebate program rules.

What About Federal Employee Plans?

The Federal Employees Health Benefits Program (FEHBP) covers more than 8 million federal employees, retirees, and dependents. Since 2024, the Office of Personnel Management has required FEHBP plans to cover anti-obesity GLP-1 medications, making federal employees one of the most consistently covered groups for obesity treatment.

Major FEHBP plans include the Blue Cross Blue Shield Service Benefit Plan, GEHA, NALC, Mail Handlers Benefit Plan, APWU Health Plan, and Aetna FEHBP. All cover Wegovy and Zepbound for obesity in 2026, with prior authorization typically requiring BMI of 30 or BMI of 27 with comorbidities.

The Postal Service Health Benefits Program (PSHBP) launched January 1, 2025 to replace FEHBP for postal workers. PSHBP plans follow similar coverage requirements for anti-obesity medications.

What About Employer Plans?

About 50% of large employer health plans (employers with 1,000+ workers) covered Wegovy or Zepbound for obesity in 2025, according to a Business Group on Health survey. The figure is up from roughly 25% in 2023 but represents a meaningful gap.

Coverage decisions are driven by cost concerns. A KFF Employer Health Benefits Survey found that employers offering anti-obesity GLP-1 coverage saw average GLP-1 spending of $200 to $400 per member per year, depending on uptake. Some large employers have implemented utilization management programs to control costs, including required lifestyle intervention trials, BMI thresholds, and discontinuation criteria for patients who don’t achieve weight loss benchmarks.

Smaller employers (under 200 workers) cover anti-obesity GLP-1s at lower rates, roughly 30 to 35% in 2025. Mid-sized employers (200 to 1,000 workers) fall in between.

What About Marketplace and Individual Plans?

Affordable Care Act marketplace plans are highly variable on anti-obesity GLP-1 coverage. The Department of Health and Human Services finalized a rule in 2025 specifying that ACA marketplace plans may but are not required to cover anti-obesity medications.

Individual plans on healthcare.gov and state exchanges typically cover GLP-1s for diabetes indications. Cardiovascular-indicated Wegovy and OSA-indicated Zepbound coverage is broad but not universal. Obesity-only coverage exists in some marketplace plans but is generally less consistent than employer-sponsored coverage.

Patients enrolling in marketplace plans should review the specific plan formulary document during open enrollment to verify coverage. Plans differ within the same state and even within the same insurance carrier.

What About the VA and Tricare?

The Department of Veterans Affairs covers Wegovy and Zepbound for veterans meeting clinical criteria, typically BMI of 30 or BMI of 27 with comorbidities. The VA negotiates substantially lower prices than commercial markets under the Federal Supply Schedule.

TRICARE, which covers active-duty military and dependents, covers Wegovy and Zepbound for the OSA and cardiovascular indications but generally not for obesity alone in most regions. Coverage decisions are made by the Defense Health Agency and updated periodically.

What If My Plan Doesn’t Cover GLP-1s?

Three pathways exist for patients without insurance coverage for their needed indication:

Manufacturer direct programs. LillyDirect Zepbound vials at $349 to $499 per month. NovoCare Wegovy at $499 per month. Both require cash payment and offer significant discounts versus list prices.

Pharmaceutical assistance programs. Both Novo Nordisk and Eli Lilly run patient assistance programs for low-income patients, with eligibility typically capped at 400% of federal poverty level for free or reduced-cost product.

Compounded GLP-1 telehealth. Personalized compounded semaglutide and tirzepatide remain available under section 503A of the Federal Food, Drug, and Cosmetic Act. Pricing typically runs $150 to $400 per month through licensed telehealth providers like TrimRx, which offers a free assessment quiz to determine eligibility for a personalized treatment plan.

How Do I Check What My Insurance Covers?

Three steps to verify coverage:

Check the plan formulary document. Insurance plans publish formulary documents listing covered drugs, tier placement, and prior authorization requirements. These are available on the plan’s website or through the pharmacy benefit manager portal.

Call the pharmacy benefit number on the back of the insurance card. Pharmacy benefit specialists can verify whether a specific drug is covered, what the copay would be, and what prior authorization is required.

Work with the prescribing clinician’s office. Most clinical offices have insurance verification staff who can run pharmacy benefit checks before prescribing. This is especially common for GLP-1 therapy given the cost and PA complexity.

Bottom line: The Inflation Reduction Act capped Part D out-of-pocket spending at $2,000 annually starting in 2025

FAQ

Does Insurance Cover Wegovy in 2026?

Most commercial insurance plans cover Wegovy for cardiovascular risk reduction in adults with overweight or obesity plus existing cardiovascular disease, based on the March 2024 FDA approval. About 50% of large employer plans also cover Wegovy for obesity alone. Medicare Part D covers Wegovy for cardiovascular indications but not pure weight loss. Most state Medicaid programs do not cover Wegovy for obesity.

Which Insurance Plans Cover Zepbound?

Most commercial insurance plans cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, based on the December 2024 FDA approval. About half of large employer plans cover Zepbound for obesity alone. Medicare Part D covers Zepbound for the OSA indication but not pure weight loss.

Does Ozempic Require Insurance Approval?

Yes, in most cases. Ozempic is covered for type 2 diabetes by essentially all commercial and government insurance plans, but prior authorization is common. Approval typically requires documentation of type 2 diabetes diagnosis and may require trial of metformin or other first-line agents in some plans.

Will My Insurance Cover GLP-1 for Weight Loss?

It depends on your specific plan. About 50% of large employer plans cover Wegovy or Zepbound for obesity in 2026. Smaller employer plans cover at lower rates. Medicare Part D cannot cover pure weight loss indications. Most state Medicaid programs do not cover obesity-indicated GLP-1s. Federal employees and many cardiovascular-indicated patients have broader coverage.

What Is Prior Authorization for GLP-1?

Prior authorization is an insurance requirement that the prescribing clinician submit documentation supporting the medical need for the drug. Typical GLP-1 prior auth requirements include qualifying diagnosis, BMI threshold (30 or 27 with comorbidities), documentation of lifestyle intervention attempt, and sometimes step therapy trial of older drugs.

What If I Can’t Afford GLP-1 Even with Insurance?

Manufacturer copay cards from Lilly and Novo Nordisk can reduce out-of-pocket costs to $25 per month for commercially insured patients. Patient assistance programs offer free or reduced-cost product for low-income patients. Manufacturer direct programs offer cash pricing at $349 to $499 per month. Licensed telehealth providers like TrimRx offer compounded GLP-1s at $150 to $400 per month.

Does Insurance Cover Compounded GLP-1?

Generally no. Insurance plans cover FDA-approved branded products including Ozempic, Mounjaro, Wegovy, and Zepbound. Compounded semaglutide and tirzepatide are typically paid cash through telehealth platforms. Some patients use insurance for branded products when their indication is covered, and others choose compounded options for cash savings when their indication isn’t covered.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.